Pharmacokinetics and Safety of Moxifloxacin
- Registration Number
- NCT01329250
- Lead Sponsor
- University Medical Center Groningen
- Brief Summary
The main objective of this prospective clinical trial is to compare pharmacokinetics and safety and tolerability of a standard dose (400 mg) with an escalated dose (600 mg; 800 mg) of moxifloxacin (MFX). This clinical trial will provide important safety information on MFX in a higher dosage in TB patients.
- Detailed Description
Moxifloxacin (MFX) is a fluoroquinolone with a high in vitro and in vivo bactericidal activity against Mycobacterium tuberculosis. A daily dose of 600-800 mg MFX should be considered for optimal killing of the involved mycobacteria and suppression of drug resistance, which is higher than the currently used dose of 400 mg once daily. In general, safety data to support switching to the suggested higher dose are limited.
For this purpose, twenty tuberculosis patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 9
- Patients with TB, with Mycobacterium tuberculosis (or M. africanum) by culture
- Starting treatment with MFX in a dose of 400 mg as part of their TB treatment
- Contra-indication for MFX
- Baseline QTc-interval > 450 msec
- History of resuscitation
- History of ventricular tachycardia (including Torsades de Pointes)
- Family history of sudden cardiac death or Torsades de Pointes
- Additional risk factors for Torsades de Pointes (including known heart failure, Left ventricular hypertrophy)
- Use of concomitant treatment with QT/QTc prolonging drugs (including anti-dysrhythmics class IA and III, antipsychotics, tricyclic antidepressants or the antihistaminic drug terfenadine)
- Abnormal electrolytes (K, Mg, Na, Ca)
- Abnormal cardiac repolarisation on screening/baseline ECG
- History of adverse events to fluoroquinolones
- HIV co-infection
- RIF treatment during last 3 weeks before start of the study. After a washout period of 3 weeks the patient can be included.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Moxifloxacin Moxifloxacin Moxifloxacinin escalating dose
- Primary Outcome Measures
Name Time Method Bound area under the plasma concentration-time curve (AUC0-24h) relative to the minimal inhibitory concentration (MIC) 21 days post dosage % of patients who will reach an AUC0-24h/MIC ratio of at least 100 after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin
Unbound AUC0-24h/MIC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis 21 days post dosage % of patients who will reach an unbound AUC0-24h/MIC ratio of at least 60 after administration of 800 mg (21 days post dosage) moxifloxacin.
Bound AUC0-24h/Mutant Prevention Concentration (MPC) ratio 21 post dosage % of patients who will reach an adequate AUC0-24h/MPC ratio of at least 93 after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin
Unbound AUC0-24h/MPC ratio as predictive parameter for efficacy of unbound MFX dose escalated treatment of tuberculosis and suppression of MFX resistance 21 days post dosage % of patients who will reach an unbound AUC0-24h/MPC ratio of at least 53 after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin
% of patients having adverse effects, including QT interval prolongation, hypersensitive reactions, diarrhoea, vomiting and hepatic or renal injury up to 21 days * QT interval in msec
* Percentage of patients developing hepatic toxicity grade ≥ 2 or 3 Common Toxicity Criteria (CTC)
* Percentage of patients developing renal toxicity grade ≥ 2 CTC
- Secondary Outcome Measures
Name Time Method Evaluation of the predictive performance of the limited sampling strategies based on a pharmacokinetic population model to calculate AUC0-24h. Several limited sampling points will be evaluated. 21 days post dosage Several limited sampling strategies to predict moxifloxacin AUC0-24h, based on limited sampling points, will be evaluated after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin
Correlation between MFX concentration (mg/L) and QT interval (msec) 21 days post dosage Correlation between MFX concentration (mg/L) and QT interval (msec) after administration of 800 mg (i.e. 21 days post dosage) moxifloxacin
Correlation of drug exposure (AUC) and adverse effects up to 21 days * vomiting and diarrhoea
* QT interval (msec)Correlation between the genetic risk score and MFX induced QT prolongation up to 21 days
Trial Locations
- Locations (1)
University Medical Center Groningen
🇳🇱Groningen, Netherlands